Jane Street Group LLC Has $522,000 Stock Position in Surmodics, Inc. (NASDAQ:SRDX)

Jane Street Group LLC lowered its stake in shares of Surmodics, Inc. (NASDAQ:SRDX) by 36.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,459 shares of the company’s stock after selling 7,752 shares during the period. Jane Street Group LLC owned approximately 0.09% of Surmodics worth $522,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Principal Financial Group Inc. acquired a new position in shares of Surmodics during the third quarter valued at about $1,190,000. Renaissance Technologies LLC raised its holdings in shares of Surmodics by 5.0% during the second quarter. Renaissance Technologies LLC now owns 606,538 shares of the company’s stock valued at $25,499,000 after purchasing an additional 28,990 shares during the period. Gardner Lewis Asset Management L P acquired a new position in shares of Surmodics during the second quarter valued at about $8,531,000. Sagefield Capital LP acquired a new stake in shares of Surmodics in the 2nd quarter worth about $2,350,000. Finally, Trium Capital LLP acquired a new stake in shares of Surmodics in the 2nd quarter worth about $1,406,000. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Trading Down 0.4 %

NASDAQ:SRDX opened at $39.52 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.96. The firm has a market cap of $564.90 million, a price-to-earnings ratio of -48.79 and a beta of 1.22. Surmodics, Inc. has a 52 week low of $25.17 and a 52 week high of $42.44. The firm has a 50-day moving average price of $39.17 and a two-hundred day moving average price of $39.80.

Surmodics (NASDAQ:SRDX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.14. The firm had revenue of $33.23 million during the quarter, compared to analyst estimates of $30.69 million. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%. On average, equities analysts expect that Surmodics, Inc. will post 0.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on SRDX. StockNews.com began coverage on shares of Surmodics in a report on Thursday. They issued a “hold” rating on the stock. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a report on Thursday, November 7th. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, Surmodics presently has a consensus rating of “Hold” and a consensus target price of $50.00.

Insider Buying and Selling at Surmodics

In other Surmodics news, CFO Timothy J. Arens sold 7,009 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the sale, the chief financial officer now owns 70,350 shares in the company, valued at approximately $2,774,604. This trade represents a 9.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 8.90% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).